In a landmark moment for Canadian medicine, Basel Abushawish has become the first patient in Canada to receive HEMGENIX, a gene therapy treatment for adults with hemophilia B. Speaking with CTV News via Zoom, Abushawish shared his experience as the pioneer of this innovative therapy.
A New Era in Hemophilia Treatment
HEMGENIX, developed by CSL Behring, offers a potential cure for hemophilia B by enabling the body to produce its own clotting factor. Unlike traditional treatments that require frequent infusions, this one-time gene therapy aims to reduce or eliminate bleeding episodes. Abushawish's successful treatment represents a significant step forward for patients living with this rare bleeding disorder.
Patient's Journey
Basel Abushawish, who has lived with hemophilia B his entire life, expressed gratitude for being selected as the first recipient. He described the procedure as smooth and highlighted the hope it brings for a normal life without constant fear of bleeds. The treatment involves a single intravenous infusion of the gene therapy vector, which delivers a functional copy of the factor IX gene to liver cells.
Impact on Canadian Healthcare
This milestone underscores Canada's role in advancing gene therapy. The approval of HEMGENIX by Health Canada in 2023 paved the way for its use. Experts believe this could reduce the burden on healthcare systems by decreasing hospital visits and improving quality of life for patients. Further studies will monitor long-term efficacy and safety.
As Abushawish continues his recovery, his case serves as a beacon of hope for the hemophilia community, demonstrating the transformative potential of gene therapy.
